Lateral Flow Technology for Field-Based Applications—Basics and Advanced Developments

O’Farrell, Brendan

doi:10.1053/j.tcam.2015.12.003

Cited by 54 publications

(40 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of a smart phone to power NATs is in development and will play an important role in future POC applications 60,61 . In particular, there has been considerable interest shown in utilizing mobile phones as readers and connectivity for RDTs using RFID (radio frequency identification) to prevent errors in subjective interpretation and transcription [62][63][64][65] . While phone-based diagnostics are attractive as an option, regulatory approval and rapid updates of phone software that can affect test performance are important challenges.…”

Section: Factors Associated With Successful Assured Diagnosticsmentioning

confidence: 99%

REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes

et al. 2018

View full text Add to dashboard Cite

Section: Factors Associated With Successful Assured Diagnosticsmentioning

confidence: 99%

REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes

et al. 2018

View full text Add to dashboard Cite

“…Where laboratory-based disease confirmation is limited, there is a high demand for user-friendly and reliable low-cost diagnostic tools that rely neither on specific laboratory facilities nor on compound logistics. Lateral flow devices (LFDs), also known as rapid immunodiagnostic tests (RIDTs), immunodiagnostic assays or immunochromatographic strip tests, offer a promising alternative to conventional diagnostic methods and have the potential to strengthen prevention and control efforts in low-resource settings [17]. These LFDs are principally based on colloidal gold conjugated monoclonal antibodies that capture the antigen within a sample.…”

Section: Introductionmentioning

confidence: 99%

Further Evidence of Inadequate Quality in Lateral Flow Devices Commercially Offered for the Diagnosis of Rabies

Fahrion

Finke

Eyngor³

et al. 2020

TropicalMed

View full text Add to dashboard Cite

As a neglected zoonotic disease, rabies causes approximately 5.9 × 104 human deaths annually, primarily affecting low- and middle-income countries in Asia and Africa. In those regions, insufficient surveillance is hampering adequate medical intervention and is driving the vicious cycle of neglect. Where resources to provide laboratory disease confirmation are limited, there is a need for user-friendly and low-cost reliable diagnostic tools that do not rely on specialized laboratory facilities. Lateral flow devices (LFD) offer an alternative to conventional diagnostic methods and may strengthen control efforts in low-resource settings. Five different commercially available LFDs were compared in a multi-centered study with respect to their diagnostic sensitivity and their agreement with standard rabies diagnostic techniques. Our evaluation was conducted by several international reference laboratories using a broad panel of samples. The overall sensitivities ranged from 0% up to 62%, depending on the LFD manufacturer, with substantial variation between the different laboratories. Samples with high antigen content and high relative viral load tended to test positive more often in the Anigen/Bionote test, the latter being the one with the best performance. Still, the overall unsatisfactory findings corroborate a previous study and indicate a persistent lack of appropriate test validation and quality control. At present, the tested kits are not suitable for in-field use for rabies diagnosis, especially not for suspect animals where human contact has been identified, as an incorrect negative diagnosis may result in human casualties. This study points out the discrepancy between the enormous need for such a diagnostic tool on the one hand, and on the other hand, a number of already existing tests that are not yet ready for use.

show abstract

“…Some assays achieve high specificity by focusing on antibody-antigen interactions that form very rapidly. For example, in lateral flow devices each protein may have to be bound in seconds as it passes an immobilized capture antibody, thereby discriminating against nonspecific interaction with a slower on-rate [26,27]. Conversely, many assays require antibodies to remain bound to their target molecules for an extended time, again minimizing background from low-affinity interactions.…”

Section: What Affinity Reagents To Use?mentioning

confidence: 99%

A myopic perspective on the future of protein diagnostics

Landegren

Al-Amin

Björkesten

2017

Preprint

View full text Add to dashboard Cite

Plasma proteome analyses of the future promise invaluable insights into states of health, not only by measuring proteins whose role it is to ensure blood homeostasis, but increasingly also as a window into the health of practically any tissue in the body via so-called leakage protein biomarkers. Realizing more of this vast potential will require progress along many lines. Here we discuss the main ones, such as optimal selection of target proteins, affinity reagents, immunoassay formats, samples, and applications, with a view from ongoing work in our laboratory.

show abstract

Lateral Flow Technology for Field-Based Applications—Basics and Advanced Developments

Cited by 54 publications

References 1 publication

REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes

REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes

Further Evidence of Inadequate Quality in Lateral Flow Devices Commercially Offered for the Diagnosis of Rabies

A myopic perspective on the future of protein diagnostics

Contact Info

Product

Resources

About